Q2 EPS Forecast for Ensysce Biosciences Lifted by Analyst

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Equities research analysts at Zacks Research raised their Q2 2026 earnings per share (EPS) estimates for shares of Ensysce Biosciences in a research note issued on Monday, May 18th. Zacks Research analyst B. Sorensen now expects that the company will post earnings of ($0.50) per share for the quarter, up from their prior estimate of ($0.71). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.98) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.98) EPS and FY2027 earnings at ($0.11) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ensysce Biosciences presently has an average rating of “Sell”.

Ensysce Biosciences Stock Performance

NASDAQ:ENSC opened at $0.32 on Monday. Ensysce Biosciences has a 52-week low of $0.23 and a 52-week high of $2.75. The firm has a market cap of $4.68 million, a price-to-earnings ratio of -0.10 and a beta of 0.87. The business’s fifty day moving average is $0.45 and its 200 day moving average is $0.86.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.21. Ensysce Biosciences had a negative return on equity of 766.45% and a negative net margin of 250.39%.The company had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.00 million.

Hedge Funds Weigh In On Ensysce Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Ensysce Biosciences in the 3rd quarter worth about $34,000. Citadel Advisors LLC bought a new position in Ensysce Biosciences in the 3rd quarter worth about $34,000. DRW Securities LLC increased its stake in Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after acquiring an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after acquiring an additional 75,000 shares during the last quarter. 5.63% of the stock is currently owned by institutional investors.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.